Development of response-selective agonists of human C5a anaphylatoxin

Conformational, biological, and therapeutic considerations

Stephen M. Taylor, Simon Sherman, Leonid Kirnarsky, Sam D. Sanderson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Numerous studies on the relationship between the structure and function of peptide agonists derived from the biologically active, C-terminal region of human C5a anaphylatoxin have been reported over the past decade. These studies have been performed with the objective of parlaying this structure-function information into the design of peptide/peptidomimetic modulators of C5a receptor (C5aR)-mediated function. In this review, we describe a rational approach for the development of conformationally biased, decapeptide agonists of C5a and described how these stabilized and specific conformational features relate to the expression of specific C5a-like activities in vitro and in vivo. The therapeutic potential of such response-selective C5a agonists is discussed and underscored by the results of one such response-selective C5a agonist that was used in vivo as an effective molecular adjuvant capable of generating antigen-specific humoral and cellular immune responses. Finally, we describe the synthesis of a new generation of highly response-selective, conformationally biased C5a agonist and discuss the in vitro and in vivo biologic results that so indicate this biologic selectivity.

Original languageEnglish (US)
Pages (from-to)675-684
Number of pages10
JournalCurrent Medicinal Chemistry
Volume8
Issue number6
DOIs
StatePublished - Jan 1 2001

Fingerprint

Anaphylatoxins
Anaphylatoxin C5a Receptor
Peptidomimetics
Peptides
Humoral Immunity
Cellular Immunity
Antigens
Modulators
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Development of response-selective agonists of human C5a anaphylatoxin : Conformational, biological, and therapeutic considerations. / Taylor, Stephen M.; Sherman, Simon; Kirnarsky, Leonid; Sanderson, Sam D.

In: Current Medicinal Chemistry, Vol. 8, No. 6, 01.01.2001, p. 675-684.

Research output: Contribution to journalArticle

@article{638b8f1abb674b1bb5d25ee7cb5d82ac,
title = "Development of response-selective agonists of human C5a anaphylatoxin: Conformational, biological, and therapeutic considerations",
abstract = "Numerous studies on the relationship between the structure and function of peptide agonists derived from the biologically active, C-terminal region of human C5a anaphylatoxin have been reported over the past decade. These studies have been performed with the objective of parlaying this structure-function information into the design of peptide/peptidomimetic modulators of C5a receptor (C5aR)-mediated function. In this review, we describe a rational approach for the development of conformationally biased, decapeptide agonists of C5a and described how these stabilized and specific conformational features relate to the expression of specific C5a-like activities in vitro and in vivo. The therapeutic potential of such response-selective C5a agonists is discussed and underscored by the results of one such response-selective C5a agonist that was used in vivo as an effective molecular adjuvant capable of generating antigen-specific humoral and cellular immune responses. Finally, we describe the synthesis of a new generation of highly response-selective, conformationally biased C5a agonist and discuss the in vitro and in vivo biologic results that so indicate this biologic selectivity.",
author = "Taylor, {Stephen M.} and Simon Sherman and Leonid Kirnarsky and Sanderson, {Sam D.}",
year = "2001",
month = "1",
day = "1",
doi = "10.2174/0929867013373156",
language = "English (US)",
volume = "8",
pages = "675--684",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Development of response-selective agonists of human C5a anaphylatoxin

T2 - Conformational, biological, and therapeutic considerations

AU - Taylor, Stephen M.

AU - Sherman, Simon

AU - Kirnarsky, Leonid

AU - Sanderson, Sam D.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Numerous studies on the relationship between the structure and function of peptide agonists derived from the biologically active, C-terminal region of human C5a anaphylatoxin have been reported over the past decade. These studies have been performed with the objective of parlaying this structure-function information into the design of peptide/peptidomimetic modulators of C5a receptor (C5aR)-mediated function. In this review, we describe a rational approach for the development of conformationally biased, decapeptide agonists of C5a and described how these stabilized and specific conformational features relate to the expression of specific C5a-like activities in vitro and in vivo. The therapeutic potential of such response-selective C5a agonists is discussed and underscored by the results of one such response-selective C5a agonist that was used in vivo as an effective molecular adjuvant capable of generating antigen-specific humoral and cellular immune responses. Finally, we describe the synthesis of a new generation of highly response-selective, conformationally biased C5a agonist and discuss the in vitro and in vivo biologic results that so indicate this biologic selectivity.

AB - Numerous studies on the relationship between the structure and function of peptide agonists derived from the biologically active, C-terminal region of human C5a anaphylatoxin have been reported over the past decade. These studies have been performed with the objective of parlaying this structure-function information into the design of peptide/peptidomimetic modulators of C5a receptor (C5aR)-mediated function. In this review, we describe a rational approach for the development of conformationally biased, decapeptide agonists of C5a and described how these stabilized and specific conformational features relate to the expression of specific C5a-like activities in vitro and in vivo. The therapeutic potential of such response-selective C5a agonists is discussed and underscored by the results of one such response-selective C5a agonist that was used in vivo as an effective molecular adjuvant capable of generating antigen-specific humoral and cellular immune responses. Finally, we describe the synthesis of a new generation of highly response-selective, conformationally biased C5a agonist and discuss the in vitro and in vivo biologic results that so indicate this biologic selectivity.

UR - http://www.scopus.com/inward/record.url?scp=0035046646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035046646&partnerID=8YFLogxK

U2 - 10.2174/0929867013373156

DO - 10.2174/0929867013373156

M3 - Article

VL - 8

SP - 675

EP - 684

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 6

ER -